TET Testosterone Treatment on Clinical Medicine

[RMontana]

Dr Abe Morgentaler interviewed on Grand Rounds on 'Saturation Theory' and testosterone treatment for men with and without prostate cancer. His conclusions are that testosterone above a level of 240-250 ng/ml dont affect progression, or initiation of prostate cancer. If true this makes the need to take TET to zero during ADT treatment not only needless, but harmful for men. Its a bold premise that goes back to Dr Huggin's original 1941 study on which most SOC for TET supplementation is based. The original study concludes with the statement that, "Testosterone activates prostate cancer." This conclusion was based on (wait for it) one man given TET supplements for 2 weeks...I am not kidding. So I underwent 21 months of ADT with TET below 10 ng/dl for what reason exactly? And now I may be at risk that it never comes back? There are many things in the current SOC that are treatment 'over kill,' low TET being one of supreme importance to men and QOL. The high points of the interview, its LINK and Dr Morgentaler's medical paper used in the interview are included.

Min 4:18; testosterone is a brain hormone.

Min 7:00; testosterone does not cause, propagate, or worsen prostate cancer.

Min 11:05; belief that testosterone is dangerous in prostate cancer Patients is not founded on any research.

Min 13:25; Dr Huggins, 1941 publication is the current basis for SOC. States; “Testosterone activates prostate cancer.” Conclusion was founded on three patients given testosterone for two weeks after which only 1 man’s results were published.

Min 14:52; Saturation Theory. BPH, PSA and tumor volume are not correlated with testosterone levels. A paradox exists. Lowering testosterone always lowers PSA, but increasing testosterone does not increase PSA; it rises but then levels off.

Min 16:35; prostate cancer needs testosterone, but the saturation point above which these cells cannot use more testosterone is reached at a low level, 240–250 ng/dL.

Min 18:35; men with prostate cancer, who receive testosterone are at no greater risk of progression than those that do not receive it.

Min 20:10; testosterone deficiency is associated with significant health issues that affect men. Diabetes, osteoporosis, dementia, metabolic blood effects, sexual function, and others.

Min 21:20; Australian study of 1000 men treated with and without testosterone. After two years, the incidence of diabetes was 50% less in those treated with testosterone. Some that started with diabetes that were treated with testosterone were cured.

youtu.be/Nemzbt6y1cs(Not working as expected?)

pubmed.ncbi.nlm.nih.gov/256...

[Seasid]

Very interesting.

[Ramp7]

Listening

[Ramp7]

So with this presentation and an understanding of BAT, it sort of makes sense. Altering the environment of the cancer causes stress. Too much or too little.

[Ramp7]

youtube.com/watch?v=wafNZV-...(Not working as expected?)

[RMontana in reply to Ramp7]

...ditto. Its astonishing that we have been treated with a regime that is based on the published results of one man, 60 years after the fact. Its said that it takes 50 years to get a bad idea out of medicine and 100 to get a good one introduced...I think they were off on the latter by a factor of 2...I digested the 2d podcast and it corroborates the Feb23 treatment of this issue...to say I feel foolish for being on ADT for 21 months and suffering the effects of a 'therapudic poison,' is understatement...it appears that what is needed is to take T to 200-250...below that you are just causing colateral damage...the cancer will progress at a T of 0 or a T of 250...makes little statistical difference from what I can see...TNX

Testosterone Therapy in Men w Advanced PCa

Min 0:58; hi testosterone causes prostate cancer Lote is protective and raising tea in a man with prostate cancer propagates disease. SOC 60 years.

Min 4:05; testosterone is a brain hormone. It activates sexual function in the brain.

Min 7:02; study 77 men with low testosterone, had similar incidence of prostate cancer as men with positive DRE or high PSA. Testosterone was not protective.

Min 9:10; during the PSA era 1985 to 2004 there were no published articles on the relationship between testosterone and prostate cancer. None, zero.

Min 10:02; Huggins, 1941 article cancer of the prostate is activated by testosterone injections.

Min 12:02; basis of 1941 paper rests on one male non-castrated patient. The total number of men evaluate it was three and only two had reported results. This is the basis of 60 years of treatment.

Min 13:38; saturation model is proposed. Rising testosterone does not correlate with more aggressive or increase prostate cancer.

Min 15:25; PSA concentrations are Androgen dependent. The saturation point is approximately 250 ng/dL. Testosterone above this level is not metabolized by prostate cancer cells.

Min 16:55; high-grade cancer is correlated with low testosterone levels.

Min 18:15; testosterone therapy after radical prostatectomy in 103 men. Progression was four times higher in men without testosterone therapy.

Min 22:30; 38,000 men in study, 5-year cumulative, incidence for prostate cancer. Men treated with testosterone had lower incidence of prostate cancer 2.8% vs 3.8%.

Min 24:40; a revolution in our understanding of testosterone and prostate cancer. Some contemporary conclusions are noted.

Min 31:26; BAT bipolar androgen therapy. Study 16 men. Cycles of 4 week injections with high-dose T followed by ADT shows PSA decline in 50% and half had reduced nodal mass.